Home
Mission
The mission of the Center for Neurodegenerative Disease Research (CNDR) is to promote and conduct multidisciplinary clinical and basic research to increase the understanding of the causes and mechanisms leading to brain dysfunction and degeneration in neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Lewy body dementia (LBD), Frontotemporal degeneration (FTD), Amyotrophic lateral sclerosis (ALS), Primary lateral sclerosis (PLS), Motor neuron disease (MND), and related disorders that occur increasingly with advancing age. Implicit in the mission of the CNDR are two overarching goals: 1.) Find better ways to cure and treat these disorders, 2. Provide training to the next generation of scientists.
1bda“My vision for CNDR is to create a world with effective interventions to prevent and cure aging-related neurodegenerative diseases.” – Eddie Lee, MD, PhD, Director of CNDR
John Q. Trojanowski, MD, PhD | 1946 - 2022
In loving memory of John Q. Trojanowski, MD, PhD
Latest Research
-
The Ecology of Care in Parkinson's Disease
Wednesday, June 10, 2026
No abstract
-
USING METAPHOR ANALYSIS TO UNDERSTAND PERSONAL AND FAMILIAL EXPERIENCES WITH BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA
Wednesday, June 10, 2026
Frontotemporal dementia (FTD) is a progressive neurodegenerative condition that causes changes in behavior, personality, and language. As researchers better understand the genetic components of FTD, the number of people pursuing genetic testing, either due to their own symptoms of FTD or their family history, is increasing, making it important to understand the impact of genetic diagnosis on lived experience. Individuals may use metaphors to describe, process, and make sense of their experiences...
-
Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE)
Monday, June 8, 2026
INTRODUCTION: Blood-based Alzheimer's disease (AD) biomarkers are increasingly used in clinical care, but there are few real-world studies of their clinical utility. We evaluated the impact of plasma phosphorylated tau at threonine 181 (p-tau181) on the diagnosis and management of patients with cognitive impairment in a memory clinic.